Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Gains from Investment Securities: 2022-2023

Historic Gains from Investment Securities for Centessa Pharmaceuticals (CNTA) over the last 2 years, with Dec 2023 value amounting to $9.7 million.

  • Centessa Pharmaceuticals' Gains from Investment Securities fell 87.11% to $125,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $125,000, marking a year-over-year decrease of 99.06%. This contributed to the annual value of $9.7 million for FY2023, which is 4814.08% up from last year.
  • According to the latest figures from FY2023, Centessa Pharmaceuticals' Gains from Investment Securities is $9.7 million, which was up 4,814.08% from -$206,000 recorded in FY2022.
  • Over the past 5 years, Centessa Pharmaceuticals' Gains from Investment Securities peaked at $9.7 million during FY2023, and registered a low of -$206,000 during FY2022.
  • Its 2-year average for Gains from Investment Securities is $4.8 million, with a median of $4.8 million in 2022.
  • Data for Centessa Pharmaceuticals' Gains from Investment Securities shows a peak YoY surged of 4,814.08% (in 2023) over the last 5 years.
  • Centessa Pharmaceuticals' Gains from Investment Securities (Yearly) stood at -$206,000 in 2022, then spiked by 4,814.08% to $9.7 million in 2023.